344 related articles for article (PubMed ID: 25572747)
41. Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.
Riedl MA; Banerji A; Manning ME; Burrell E; Joshi N; Patel D; Machnig T; Tai MH; Watson DJ
Orphanet J Rare Dis; 2018 Oct; 13(1):180. PubMed ID: 30314518
[TBL] [Abstract][Full Text] [Related]
42. How satisfactory is on-demand icatibant from the patients' perspective in real life?
Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
[No Abstract] [Full Text] [Related]
43. Successful perioperative management of a patient with C1 esterase inhibitor deficiency with a novel bradykinin receptor B2 antagonist.
Senaratne KT; Cottrell AM; Prentice RI
Anaesth Intensive Care; 2012 May; 40(3):523-6. PubMed ID: 22577920
[TBL] [Abstract][Full Text] [Related]
44. The Angiotensin-Converting-Enzyme-Induced Angioedema.
Bas M
Immunol Allergy Clin North Am; 2017 Feb; 37(1):183-200. PubMed ID: 27886906
[TBL] [Abstract][Full Text] [Related]
45. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.
Zanichelli A; Mansi M; Periti G; Cicardi M
Expert Rev Clin Immunol; 2013 May; 9(5):477-88. PubMed ID: 23634741
[TBL] [Abstract][Full Text] [Related]
47. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema.
Castaldo AJ; Jervelund C; Corcoran D; Boysen HB; Christiansen SC; Zuraw BL
Allergy Asthma Proc; 2021 Mar; 42(2):108-117. PubMed ID: 33581742
[No Abstract] [Full Text] [Related]
48. Icatibant in angiotensin-converting enzyme (ACE) inhibitor-associated angioedema.
Fok JS; Katelaris CH; Brown AF; Smith WB
Intern Med J; 2015 Aug; 45(8):821-7. PubMed ID: 25944565
[TBL] [Abstract][Full Text] [Related]
49. When is prophylaxis for hereditary angioedema necessary?
Craig T; Riedl M; Dykewicz MS; Gower RG; Baker J; Edelman FJ; Hurewitz D; Jacobs J; Kalfus I
Ann Allergy Asthma Immunol; 2009 May; 102(5):366-72. PubMed ID: 19492656
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment of acute hereditary angioedema attacks with self-administered icatibant in patients with venous access problems.
Wiednig M
BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23625675
[TBL] [Abstract][Full Text] [Related]
51. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Cicardi M; Banerji A; Bracho F; Malbrán A; Rosenkranz B; Riedl M; Bork K; Lumry W; Aberer W; Bier H; Bas M; Greve J; Hoffmann TK; Farkas H; Reshef A; Ritchie B; Yang W; Grabbe J; Kivity S; Kreuz W; Levy RJ; Luger T; Obtulowicz K; Schmid-Grendelmeier P; Bull C; Sitkauskiene B; Smith WB; Toubi E; Werner S; Anné S; Björkander J; Bouillet L; Cillari E; Hurewitz D; Jacobson KW; Katelaris CH; Maurer M; Merk H; Bernstein JA; Feighery C; Floccard B; Gleich G; Hébert J; Kaatz M; Keith P; Kirkpatrick CH; Langton D; Martin L; Pichler C; Resnick D; Wombolt D; Fernández Romero DS; Zanichelli A; Arcoleo F; Knolle J; Kravec I; Dong L; Zimmermann J; Rosen K; Fan WT
N Engl J Med; 2010 Aug; 363(6):532-41. PubMed ID: 20818888
[TBL] [Abstract][Full Text] [Related]
52. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study.
Zanichelli A; Bova M; Coerezza A; Petraroli A; Triggiani M; Cicardi M
Allergy; 2012 Aug; 67(8):1074-7. PubMed ID: 22686628
[TBL] [Abstract][Full Text] [Related]
53. [Treatment of drugs-associated non-hereditary angioedema mediated by bradykinin].
Muller Y; Harr T
Rev Med Suisse; 2016 Jan; 12(500):11-2. PubMed ID: 26946694
[TBL] [Abstract][Full Text] [Related]
54. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.
Longhurst HJ; Aberer W; Bouillet L; Caballero T; Fabien V; Zanichelli A; Maurer M;
Allergy Asthma Proc; 2015; 36(5):399-406. PubMed ID: 26314822
[TBL] [Abstract][Full Text] [Related]
55. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
Aberer W; Maurer M; Reshef A; Longhurst H; Kivity S; Bygum A; Caballero T; Bloom B; Nair N; Malbrán A
Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203
[TBL] [Abstract][Full Text] [Related]
56. The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED.
Bartal C; Zeldetz V; Stavi V; Barski L
Am J Emerg Med; 2015 Mar; 33(3):479.e1-3. PubMed ID: 25241359
[TBL] [Abstract][Full Text] [Related]
57. Real-world off-label use of icatibant for acute management of non-hereditary angioedema.
Le TA; Smith W; Hissaria P
Intern Med J; 2021 Mar; 51(3):419-423. PubMed ID: 33738947
[TBL] [Abstract][Full Text] [Related]
58. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
Krause K; Metz M; Zuberbier T; Maurer M; Magerl M
J Dtsch Dermatol Ges; 2010 Apr; 8(4):272-4. PubMed ID: 19758369
[TBL] [Abstract][Full Text] [Related]
59. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
[TBL] [Abstract][Full Text] [Related]
60. Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings.
Grumach AS; Longhurst HJ; Aberer W; Bouillet L; Caballero T; Bygum A; Zanichelli A; Botha J; Andresen I; Maurer M;
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1078-1080. PubMed ID: 30170163
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
